Enter at least 3 characters
Home > Transparency

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Text email send
Authorize the processing of personal data

 

Transparency

As a pharmaceutical company, the Chiesi Group works closely with the scientific community by constantly exchanging knowledge, achieving significant progress in the scientific world for the benefit and protection of patient health, once again in accordance with the codes and provisions regulating our sector.

This is why we fully subscribe to the principles of transparency laid down by Farmindustria and the EFPIA – European Federation of Pharmaceutical Industries and Associations – and have been working on implementing them in the most appropriate way over the past few months, certain of the relationship of mutual trust between ourselves and those we work with.

The publication of data on the transfer of value thus represents an opportunity for us to reinforce transparency in our dealings with the public and institutional bodies.

Once again we want Chiesi to be recognised by all its interlocutors as a reliable company able to promote and adopt transparent conduct at all levels in accordance with the relevant provisions and regulations, and with a sense of responsibility regarding its key role in the pharmaceutical sector.

On the basis of the regulations in the Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations, relating to the transparency of transfers of value between pharmaceutical companies, healthcare workers and organizations indicated by the EFPIA, also incorporated into the Farmindustria Deontological Code, our company is committed to making data relating to these transfers of value public each year at European level, with a view to achieving complete transparency and traceability of the operations carried out, beginning in 2015 (first publication June 30th 2016).

On Chiesi Italy’s website, our Italian affiliate, all details of the economic transactions made in 2017 for the benefit of healthcare workers and organisations are available (more details here).

With regard to healthcare workers these are to cover the cost of taking part in conferences and congresses and expenditure for consultancy activities and professional services regulated by specific contracts.

With regard to healthcare organisations these are donations and contributions, both in the form of money or in kind, sponsoring for scientific events providing effective training, payment for consultancy work and professional services covered by a written contract between Chiesi and institutions, organizations or associations.

With regard to transfers of value at corporate level for Research and Development, only the costs relating to pre-clinical, clinical and observational trials made directly or indirectly to healthcare professionals and organizations, both in Italy and abroad, are published (and therefore only a small part of the amount indicated refers to healthcare professionals and organisations located in Italy). This is therefore a part of the costs sustained annually by Chiesi for research and development: each year Chiesi invests around 20% of its turnover, which places it among the top companies in national and international rankings. In 2017 investments totalled 22.3%.

For information on the regulations introduced by the “Code on Disclosure of Transfers of Value from pharmaceutical firms, healthcare professionals and healthcare organizations” please refer to the following website: www.farmindustria.it (from the Home Page go to the Deontological Code section) or get in touch with the Chiesi Transparency Contact Point at the following email address: dpoit@chiesi.com.

For requests on the behalf of the media please contact Valentina Biagini -  Group.Communication@chiesi.com – Senior Group Communication Manager for the Chiesi Group.

ANNO 2017